Skip to main content
Premium Trial:

Request an Annual Quote

AutoGenomics Gets Health Canada OK for PGx System

NEW YORK (GenomeWeb News) – Autogenomics today said that it has received regulatory approval in Canada to market its Infiniti Pharmacogenomic testing system.

The Vista, Calif.-based firm received Health Canada Medical Device Class III approvals for the system along with two thrombolytic drug metabolism test kits, one for warfarin sensitivity and the other a 2C19 assay that indicates how a patient will metabolize commonly prescribed drugs.

The system and tests will be distributed in Canada by ESBE Scientific to labs providing clinical molecular testing services.

Autogenomics received US Food and Drug Administration clearance to market its Infiniti 2C9-VKORC1 Multiplex Assay for warfarin sensitivity in early 2008. It received FDA clearance for the Infiniti CYP2C19 assay in 2010.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.